Diana Ernst, RPh

Editorial Director https://www.neurologyadvisor.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Pain

DEA Proposes Less Opioid Production, More Marijuana for Research in 2020

Diana Ernst, RPh

September 13, 2019

The Drug Enforcement Administration (DEA) is proposing a reduction in the amount of Schedule II controlled substances that can be manufactured in the US next year.

Multiple Sclerosis

Ofatumumab Bests Teriflunomide in Head-to-Head MS Trials

Diana Ernst, RPh

September 6, 2019

Findings from the phase 3 ASCLEPIOS I and II studies showed that treatment with ofatumumab (Novartis) resulted in a highly significant and clinically meaningful reduction in the number of confirmed relapses, compared with teriflunomide, a pyrimidine synthesis inhibitor, in patients with relapsing forms of multiple sclerosis.

Neuromuscular Disorders

Myobloc Approved for the Treatment of Chronic Sialorrhea

Diana Ernst, RPh

September 5, 2019

The Food and Drug Administration (FDA) has approved Myobloc (rimabotulinumtoxinB injection; US WorldMeds) for the treatment of chronic sialorrhea in adults.

Neurobehavioral Disorders

Potential First-in-Class Treatment for Tourette Syndrome Gets Fast Track Status

Diana Ernst, RPh

September 5, 2019

The Food and Drug Administration (FDA) has granted Fast Track designation to ecopipam (Emalex Biosciences), an investigational agent for the treatment of Tourette syndrome (TS).

Neurodegenerative Diseases

Trial Investigating Fosmetpantotenate for Rare Neurologic Disorder Misses Primary End Point

Diana Ernst, RPh

August 28, 2019

A phase 3 trial evaluating an investigational therapy for the treatment of pantothenate kinase-associated neurodegeneration did not meet its primary or secondary end points.

Sleep Disorders

FDA Rejects Supplemental New Drug Application for Tasimelteon in Jet Lag Disorder

Diana Ernst, RPh

August 21, 2019

The FDA has rejected the supplemental New Drug Application for Hetlioz (tasimelteon; Vanda Pharmaceuticals) for the treatment of jet lag disorder.

Practice Management

Physician Attitudes Toward Herpes Zoster Vaccination Examined Over a Decade of Availability

Diana Ernst, RPh

August 20, 2019

Only 29% of 2016 survey respondents reported that they strongly agreed that the burden of herpes zoster in patients aged 50 to 59 years old is sufficient to make a vaccine important.

Pediatric Neurology

FDA Issues Statement Regarding Data Manipulation in Recently Approved Gene Therapy for SMA

Diana Ernst, RPh

August 7, 2019

According to the Food and Drug Administration (FDA), AveXis Inc, the manufacturer of the gene therapy Zolgensma, was aware of an issue related to “data manipulation” prior to approval, but did not inform the Agency until after the product was approved.

Migraine and Headache

Galcanezumab Beneficial for Treatment-Resistant Migraine in Phase 3 Trial

Diana Ernst, RPh

August 7, 2019

Galcanezumab was found to be beneficial in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.

Multiple Sclerosis

Diroximel Fumarate for Relapsing Remitting MS Shows Good Tolerability in Phase 3 Study

Diana Ernst, RPh

August 1, 2019

Treatment with diroximel fumarate was associated with significantly fewer days of key gastrointestinal symptoms, according to topline results from a phase 3 study evaluating the GI tolerability.

Next post in Multiple Sclerosis